Poly (ADP-ribose) polymerase inhibitors in cancer therapy [PDF]
Chinese Medical Journal. Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have emerged as critical agents for cancer therapy. By inhibiting the catalytic activity of PARP enzymes and trapping them in the DNA, PARPis disrupt DNA repair, ultimately leading to cell death ...
Ziqi Zhu, Yujun Shi, Jing Ni
doaj +5 more sources
Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer [PDF]
Frontiers in Pharmacology, 2023 Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair.
Ruihong Dong +5 more
doaj +2 more sources
Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors [PDF]
Haematologica, 2008 Poly ADP-ribose polymerase inhibitors have been shown to target cells with homologous recombination DNA repair defects. We report that poly ADP-ribose polymerase inhibitors induces apoptosis in cells deficient in other key DNA repair components ...
Terry J. Gaymes +3 more
doaj +2 more sources
Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents [PDF]
Frontiers in Oncology, 2021 BackgroundPoly ADP-ribose glycohydrolase (PARG) is responsible for the catabolism of PARP-synthesized PAR to free ADP-ribose. Inhibition of PARG leads to DNA repair interruption and consequently induces cell death.
Emad Matanes +19 more
doaj +2 more sources
R2eGIN: Residual Reconstruction Enhanced Graph Isomorphism Network for Accurate Prediction of Poly (ADP–Ribose) Polymerase Inhibitors [PDF]
Bioinformatics and Biology InsightsAn advanced graph neural network (GNN) is of great promise to facilitate predicting Poly ADPribose polymerase inhibitors (PARPi). Recent studies design models by leveraging graph representations and molecular descriptor representations, unfortunately ...
Candra Zonyfar +3 more
doaj +2 more sources
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy [PDF]
Frontiers in Chemistry, 2020 A number of poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for clinical use in BRCA mutated and other cancers. However, off-target toxicity of PARP inhibitors and the emergence of drug resistance following prolonged ...
Bijay Singh +10 more
doaj +2 more sources
Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages [PDF]
Frontiers in Immunology, 2021 Diabetes mellites (DM) is correlated with increased susceptibility to and disease progression of tuberculosis (TB), and strongly impairs effective global TB control measures.
Cassandra L. R. van Doorn +3 more
doaj +2 more sources
Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations [PDF]
Front Pharmacol, 2021 Qin Xu, Zhengyu Li
openalex +2 more sources
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations [PDF]
Int J Mol SciBenigno C. Valdez +6 more
openalex +2 more sources
PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression [PDF]
, 2015 To overcome cancer cells resistance to pharmacological therapy, the development of new therapeutic approaches becomes urgent. For this purpose, the use of poly(ADP-ribose) polymerase (PARP) inhibitors in combination with other cytotoxic agents could ...
CAIAFA, Paola +11 more
core +12 more sources